Therapeutic Implications of Acutaping on Nausea and Vomiting During Pregnancy

NCT06259747 | Completed

• 1 other identifier: Acutaping for NVP
• Study Type: interventional
• Target: 27
• Locations: 1 country
• Sites: 1

Brief Summary

This study will answer the following research question: Is acutaping has therapeutic implications on symptoms of nausea and vomiting during pregnancy?

Conditions

Nausea; Vomiting of Pregnancy

Outcome Measures

Primary Outcomes (2)

• pregnancy unique quantification of emesis and nausea questionnaire

  Frequency of nausea \& vomiting and dry heaviness without vomiting Score. detection of frequency of nausea \& vomiting and dry heaviness without vomiting , total score of frequency of nausea \& vomiting and dry heaviness without vomiting (sum of replies to 1, 2, 3 questions): Mild NVP ≤ 6, Moderate NVP 7-12, severe NVP ≥ 13.

  Measured before treatment , after first treatment (at 4th day) and after second treatment (at 8th day )

• pregnancy unique quantification of emesis and nausea questionnaire

  Quality of life in those pregnant women Score the quality of life question is on a scale of 0-10 with: 0(worst possible), 10 (as good as you felt before pregnancy).

  Measured before treatment , after first treatment (at 4th day) and after second treatment (at 8th day )

Study Arms (2)

acutaping and traditional medical treatment

EXPERIMENTAL

received acutaping in addition to traditional medical treatment (Doxylamine and Pyridoxine)

Other: Acutaping; Drug: Doxylamine and Pyridoxine

traditional medical treatment only

EXPERIMENTAL

received traditional medical treatment only (Doxylamine and Pyridoxine

Drug: Doxylamine and Pyridoxine

Interventions

Acutaping OTHER

Application of the kinesio tape on finger and forearm flexor tape after localization of the acupoints of application

acutaping and traditional medical treatment

Doxylamine and Pyridoxine DRUG

traditional medical treatment for nausea and vomiting during pregnancy

acutaping and traditional medical treatment; traditional medical treatment only

Eligibility Criteria

• Age: 20 Years - 35 Years
• Gender Eligibility Details: pregnant women
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Woman with nausea and vomiting during pregnancy Primigravida With age ranges from 20-35years Gestational age 7-16 weeks Body mass index (BMI) less than 30 kg/m2 Not hospitalized due to hyperemesis gravidarum

You may not qualify if:

• Gastrointestinal disorder Diabetes Dehydration

Sponsors & Collaborators

• Kafrelsheikh University: lead

Study Sites (1)

Damanhour teaching hospital and private clinics

Kafr ash Shaykh, Egypt

Location

MeSH Terms

Conditions

Nausea

Interventions

dicyclomine, doxylamine, pyridoxine drug combination

Condition Hierarchy (Ancestors)

Signs and Symptoms, Digestive; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• Eman Abdelfatah Elhosary, professor at women's health

  Women's Health Department ,Faculty Of Physical Therapy Kafr Elsheikh University

  STUDY DIRECTOR

• Fayiz Farouk Elshamy, professor at women's health

  Women's Health Department ,Faculty Of Physical Therapy Kafr Elsheikh University

  STUDY DIRECTOR

• Tamer Mahmoud Zaki, Fellow Obst. and gyna.

  Obestetrics And Gynecology Depatment, Damanhour Teaching Hospital

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Demonstrator at women's health department

Model Details: Participants will be randomly allocated into two groups; group (A) will receive acutaping in addition to traditional medical treatment (Doxylamine and Pyridoxine) while group (B) will receive traditional medical treatment(Doxylamine and Pyridoxine) only.

Study Record Dates

• First Submitted: February 7, 2024
• First Posted: February 14, 2024
• Study Start: February 3, 2023
• Primary Completion: December 15, 2023
• Study Completion: December 15, 2023
• Last Updated: February 16, 2024

Record last verified: 2024-02

Locations

EG (1)